Acute Ischemic Stroke in an Infant with MTHFR A1298C Homozygous Mutation: A Case Report

Abstract

Acute ischemic stroke is rare in children, but it is one of the important causes of neurological morbidity. The etiology of AIS in childhood includes cardiac pathologies, cerebral arteriopathies, hypercoagulation, chemicals, drugs, inflammatory and autoimmune causes. In this article, we present an infant who has a genetic predisposition to hypercoagulation and comes with AIS clinic when multifactorial risk factors are added. The diagnosis, the underlying etiology, the risk factors affecting the process, the treatment of acute phase, the secondary treatment and the associated preventive approach on prognosis were discussed.

Keywords

• Acute ischemic stroke
• MTHFR A1298C
• homocysteinemia
• infant

MTHFR A1298C Homozigot Gen Polimorfizmi Olan Süt Çocuğunda Akut İskemik İnme: Olgu Sunumu

Abstract

Akut iskemik inme (acute ischemic stroke-AIS) çocuklarda nadir görülmekle beraber nörolojik morbiditenin önemli nedenlerinden biridir. Çocukluk çağında AIS etyolojisinde kardiyak patolojiler, serebral arteriopatiler, hiperkoagülasyon, enfeksiyonlar, ilaçlar, inflamatuar ve otoimmün nedenler yer almaktadır. Bu makalede hiperkoagülasyona genetik yatkınlığı olan, multifaktöriyel risk faktörleri eklenince AIS kliniği ile gelen bir süt çocuğu sunulmakta olup; AIS olgularında tanı aşaması, altta yatan etyoloji, süreci etkileyen risk faktörleri, akut dönem tedavi, ikincil basamak tedavi ve beraberinde koruyucu yaklaşımın prognoz üzerindeki etkisi tartışılmıştır.

Keywords

• Akut iskemik inme
• MTHFR A1298C
• homosisteinemi
• süt çocuğu

References

1. 1. Mallick AA, Ganesan V, O’Callaghan FJ. Mortality from childhood stroke in England and Wales, 1921–2000. Arch Dis Child 2010;95:12-9.
2. 2. Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002; 288:2015-22.
3. 3. Hujar BS, Kopyta I, Skrzpek M. Is the 1298A>C polymorphism in the MTHFR gene a risk factor for arterial ischaemic stroke in children? The results of meta-analysis. Clin Exp Med 2018;18:337-45.
4. 4. Mallick AA, Ganesan V, Kirkham FJ, Fallon P, Hedderly T, McShane T, et al. Childhood arterial ischaemic stroke incidence, presenting features, and risk factors: a prospective population-based study. Lancet Neurol 2014;13(1):35-43.
5. 5. Lo WD, Kumar R. Arterial ischemic stroke in children and young adults. Continuum (Minneap Minn) 2017;23:158-80.
6. 6. Felling RJ, Sun LR, Maxwell EC, Goldenberg N, Bernard T. Pediatric arterial ischemic stroke: epidemiology, risk factors, and management. Blood Cells Mol Dis 2017;67:23-33.
7. 7. Strater R, Kurnik K, Heller C, Schobess R, Luigs P, Nowak-Gottl U. Aspirin versus low-dose low- molecular-weight heparin: antithrombotic therapy in pediatric ischemic stroke patients: a prospective follow-up study. Stroke 2001;32(11):2554-8.
8. 8. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 2000;26:341-8.

9. 9. Simonetti BG, Cavelti A, Arnold M, Bigi S, Regényi M, Mattle HP, et al. Long-term outcome after arterial ischem